Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1991-04-16
1994-04-12
Rotman, Alan L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546330, C07D21357, A61K 3144
Patent
active
053026063
ABSTRACT:
Methods of inhibiting cell proliferation in a patient suffering from such disorder comprising the use of a styryl-substituted heteroaryl compound wherein the heteroaryl group is a monocyclic ring with 1 or 2 heteroatoms, or a bicyclic ring with 1 to about 4 heteroatoms, said compound optionally substituted or polysubstituted, with the proviso that when said ring is polysubstituted, the substituents do not have a common point of attachment to said ring, and those compounds wherein no substituent on the heteroaryl group is a carboxy group or an ester group, and pharmaceutical compositions comprising such compounds.
REFERENCES:
patent: 3149148 (1964-09-01), Kladko et al.
patent: 3157663 (1964-11-01), Bencze
patent: 3196158 (1965-07-01), Bencze
patent: 3337565 (1967-08-01), Bencze et al.
patent: 3337568 (1967-08-01), Bencze et al.
patent: 4532329 (1985-07-01), Haken et al.
patent: 4539325 (1985-09-01), Heeres
patent: 4600712 (1986-07-01), Haken et al.
patent: 4626543 (1986-12-01), Kollmeyer
patent: 4678793 (1987-07-01), Klaus et al.
patent: 4769384 (1988-09-01), Kise et al.
patent: 4816476 (1989-03-01), Klaus et al.
patent: 4826984 (1989-05-01), Berlin et al.
patent: 4833247 (1989-05-01), Krause
Harrison's Principles of Internal Medicine. 8th ed. vol. 1 (1975). pp. 532-538.
Buu-Hoi et al., Journal of the Chemical Society (C), pp. 2069-2070 (1969).
Chemical Abstracts, 107(19):17642h (1987).
S. Kusuma, W. D. Wilson and D. W. Boykin, J. Heterocyclic Chem., 22, 1229 (1985).
T. Kato, T. Shiraishi and T. Atsumi, Yakugaku Zasshi, 89(2), pp. 188-193 (1969).
Gilon Chaim
Levitzki Alexander
Persons Paul E.
Spada Alfred P.
Rhone-Poulenc Rorer Pharmaceuticals Inc.
Rotman Alan L.
Spivack Phyllis
LandOfFree
Styryl-substituted pyridyl compounds which inhibit EGF receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Styryl-substituted pyridyl compounds which inhibit EGF receptor , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Styryl-substituted pyridyl compounds which inhibit EGF receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2098985